Safety considerations in the management of allergic diseases: focus on antihistamines

References

• Pawankar R, Canonica GW, Holgate ST, et al. eds. WAO White Book on Allergy. Milwaukee, WI: World Allergy Organization, 2011
   Google Scholar
• Bousquet J, Khaltaev N, Cruz AA, et al. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008;63(Suppl 86):8-160
   PubMed Web of Science ®Google Scholar
• Asha'ari ZA, Yusof S, Ismail R, et al. Clinical features of allergic rhinitis and skin prick test analysis based on the ARIA classification: a preliminary study in Malaysia. Ann Acad Med Singapore 2010;39:619-24
   PubMed Web of Science ®Google Scholar
• Samolinski B, Sybilski AJ, Raciborski F, et al. Prevalence of rhinitis in Polish population according to the ECAP (Epidemiology of Allergic Disorders in Poland) study. Otolaryngol Pol 2009;63:324-30
   PubMedGoogle Scholar
• Klossek JM, Annesi-Maesano I, Pribil C, et al. [INSTANT: national survey of allergic rhinitis in a French adult population based-sample]. Presse Med 2009;38:1220-29
   PubMed Web of Science ®Google Scholar
• Maurer M, Zuberbier T. Undertreatment of rhinitis symptoms in Europe: findings from a cross-sectional questionnaire survey. Allergy 2007;62:1057-63
   PubMed Web of Science ®Google Scholar
• Nolte H, Nepper-Christensen S, Backer V. Unawareness and undertreatment of asthma and allergic rhinitis in a general population. Respir Med 2006;100:354-62
   PubMed Web of Science ®Google Scholar
• Sih T, Mion O. Allergic rhinitis in the child and associated comorbidities. Pediatr Allergy Immunol 2010;21(1 Pt 2):e107-13
   PubMed Web of Science ®Google Scholar
• Laekeman G, Simoens S, Buffels J, et al. Continuous versus on-demand pharmacotherapy of allergic rhinitis: evidence and practice. Respir Med 2010;104:615-25
   PubMed Web of Science ®Google Scholar
• Brozek JL, Bousquet J, Baena-Cagnani CE, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010;126:466-76
   PubMed Web of Science ®Google Scholar
• Angier E, Willington J, Scadding G, et al. British Society for Allergy & Clinical Immunology (BSACI) Standards of Care Committee. Management of allergic and non-allergic rhinitis: a primary care summary of the BSACI guideline. Prim Care Respir J 2010;19:217-22
   PubMedGoogle Scholar
• Price D, Bond C, Bouchard J, et al. International Primary Care Respiratory Group (IPCRG) Guidelines: management of allergic rhinitis. Prim Care Respir J 2006;15:58-70
   PubMedGoogle Scholar
• Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy 2009;64:1427-43
   PubMed Web of Science ®Google Scholar
• Canonica GW, Blaiss M. Antihistaminic, anti-inflammatory, and antiallergic properties of the nonsedating second-generation antihistamine desloratadine: a review of the evidence. WAO Journal 2011;4:47-53
   Google Scholar
• Baroody FM, Naclerio RM. Antiallergic effects of H1-receptor antagonists. Allergy 2000;55:17-27
   PubMed Web of Science ®Google Scholar
• Church MK, Maurer M, Simons FE, et al. Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. Allergy 2010;65:459-66
   PubMed Web of Science ®Google Scholar
• Tashiro M, Mochizuki H, Iwabuchi K, et al. Roles of histamine in regulation of arousal and cognition: functional neuroimaging of histamine H1 receptors in human brain. Life Sci 2002;72:409-14
   PubMed Web of Science ®Google Scholar
• Gillman S, Gillard M, Strolin Benedetti M. The concept of receptor occupancy to predict clinical efficacy: a comparison of second generation H1 antihistamines. Allergy Asthma Proc 2009;30:366-76
   PubMed Web of Science ®Google Scholar
• Yanai K, Zhang D, Tashiro M, et al. Positron emission tomography evaluation of sedative properties of antihistamines. Expert Opin Drug Saf 2011;10:613-22
   PubMed Web of Science ®Google Scholar
• Yanai K, Tashiro M. The physiological and pathophysiological roles of neuronal histamine: an insight from human positron emission tomography studies. Pharmacol Ther 2007;113:1-15
   PubMed Web of Science ®Google Scholar
• Frossard N, Strolin-Benedetti M, Purohit A, et al. Inhibition of allergen-induced wheal and flare reactions by levocetirizine and desloratadine. Br J Clin Pharmacol 2008;65:172-29
   PubMed Web of Science ®Google Scholar
• Kubo N, Senda M, Ohsumi Y, et al. Brain histamine H1 receptor occupancy of loratadine measured by positron emission topography: comparison of H1 receptor occupancy and proportional impairment ratio. Hum Psychopharmacol 2011;26:133-39
   PubMed Web of Science ®Google Scholar
• McDonald K, Trick L, Boyle J. Sedation and antihistamines: an update. Review of inter-drug differences using proportional impairment ratios. Hum Psychopharmacol 2008;23:555-70
   PubMed Web of Science ®Google Scholar
• Shamsi Z, Hindmarch I. Sedation and antihistamines: a review of inter-drug differences using proportional impairment ratios. Hum Psychopharmacol 2000;15(S1):S3-30
   PubMedGoogle Scholar
• Wall A, Kågedal M, Bergström M, et al. Distribution of zolmitriptan into the CNS in healthy volunteers: a positron emission tomography study. Drugs R D. 2005;6:139-47
   PubMedGoogle Scholar
• Fox AW. Comparative tolerability of oral 5-HT1B/1D agonists. Headache 2000;40:521-27
   PubMed Web of Science ®Google Scholar
• Patient information leaflet for Patanase® nasal spray. Available at: http://ecatalog.alcon.com/PI/Patanase_us_en.pdf (accessed January 9th, 2012)
   Google Scholar
• Patient information leaflet for Astelin® nasal spray. Available at: http://www.astelin.com/pdf/astelin_pi.pdf (accessed January 9th, 2012)
   Google Scholar
• Wen MM. Olfactory targeting through intranasal delivery of biopharmaceutical drugs to the brain - current development. Discov Med 2011;11:497-503
   PubMed Web of Science ®Google Scholar
• Leary AC, Dowling M, Cussen K, et al. Pharmacokinetics and pharmacodynamics of intranasal insulin spray (Nasulin) administered to healthy male volunteers: influence of the nasal cycle. J Diabetes Sci Technol 2008;2:1054-60
   PubMedGoogle Scholar
• Costantino HR, Illum L, Brandt G, et al. Intranasal delivery: physicochemical and therapeutic aspects. Int J Pharm 2007;337:1-24
   PubMed Web of Science ®Google Scholar
• Wermeling DP, Record KA, Kelly TH, et al. Pharmacokinetics and pharmacodynamics of a new intranasal midazolam formulation in healthy volunteers. Anesth Analg 2006;103:344-49
   PubMed Web of Science ®Google Scholar
• Dhuria SV, Hanson LR, Frey WH 2nd. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci 2010;99:1654-73
   PubMed Web of Science ®Google Scholar
• Morrison EE, Costanzo RM. Morphology of the human olfactory epithelium. J Comp Neurol 1990;297:1-13
   PubMed Web of Science ®Google Scholar
• Ding X, Dahl AR. Olfactory mucosa: composition, enzymatic localization, and metabolism. In: Doty RL, ed. Handbook of Olfaction and Gustation, 2nd edn, Ch 3. New York: Marcel Dekker, 2003:33-52
   Google Scholar
• Zhang D, Shibuya K, Tashiro M, et al. Potential central sedative effect of antihistamine eye-drops: histamine H1 occupancy measured by positron emission tomography. J Pharmacol Sci 2011;115(Suppl 1):221P
   PubMedGoogle Scholar
• Salminen L. Review: systemic absorption of topically applied ocular drugs in humans. J Ocul Pharmacol 1990;6:243-49
   PubMedGoogle Scholar
• Chen C, Hanson E, Watson JW, et al. P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. Drug Metab Dispos 2003;31:312-18
   PubMed Web of Science ®Google Scholar
• Zhao R, Kalvass JC, Yanni SB, et al. Fexofenadine brain exposure and the influence of blood-brain barrier P-glycoprotein after fexofenadine and terfenadine administration. Drug Metab Dispos 2009;37:529-35
   PubMed Web of Science ®Google Scholar
• Mimura N, Nagata Y, Kuwabara T, et al. P-glycoprotein limits the brain penetration of olopatadine hydrochloride, H1-receptor antagonist. Drug Metab Pharmacokinet 2008;23:106-14
   PubMed Web of Science ®Google Scholar
• Molimard M, Diquet B, Benedetti MS. Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. Fundam Clin Pharmacol 2004;18:399-411
   PubMed Web of Science ®Google Scholar
• Tamai I, Kido Y, Yamashita J, et al. Blood-brain barrier transport of H1-antagonist ebastine and its metabolite carebastine. J Drug Target 2000;8:383-93
   PubMed Web of Science ®Google Scholar
• Broccatelli F, Carosati E, Neri A, et al. A novel approach for predicting P-glycoprotein (ABCB1) inhibition using molecular interaction fields. J Med Chem 2011;54:1740-51
   PubMed Web of Science ®Google Scholar
• Li C, Kim M, Choi JS. Effects of prednisolone on the pharmacokinetics of loratadine after oral and intravenous administration of loratadine in rats. Arch Pharm Res 2010;33:1395-400
   PubMed Web of Science ®Google Scholar
• Li C, Kim CS, Yang JY, et al. Effects of roxithromycin on the pharmacokinetics of loratadine after oral and intravenous administration of loratadine in rats. Eur J Drug Metab Pharmacokinet 2008;33:231-36
   PubMed Web of Science ®Google Scholar
• Katta A, Dhananjeyan M, Bykowski C, et al. Verapamil, but not probenecid, co-administration can convert desloratadine to a sedating antihistamine in mice. Drug Metab Lett 2007;1:7-11
   PubMedGoogle Scholar
• Yasui-Furukori N, Uno T, Sugawara K, et al. Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics. Clin Pharmacol Ther 2005;77:17-23
   PubMed Web of Science ®Google Scholar
• Sakugawa T, Miura M, Hokama N, et al. Enantioselective disposition of fexofenadine with the P-glycoprotein inhibitor verapamil. Br J Clin Pharmacol 2009;67:535-40
   PubMed Web of Science ®Google Scholar
• Shen S, He Y, Zeng S. Stereoselective regulation of MDR1 expression in Caco-2 cells by cetirizine enantiomers. Chirality 2007;19:485-90
   PubMed Web of Science ®Google Scholar
• Kavanagh JJ, Grant GD, Anoopkumar-Dukie S. Low dosage promethazine and loratadine negatively affect neuromotor function. Clin Neurophysiol 2011 Aug 29 [Epub ahead of print]
   Google Scholar
• Liu H, Farley JM. Effects of first and second generation antihistamines on muscarinic induced mucus gland cell ion transport. BMC Pharmacology 2005;5:8 doi:10.1186/1471-2210-5-8
   PubMedGoogle Scholar
• Rico S, Antonijoan R, Barbanoj M. Ebastine in the light of CONGA recommendations for the development of third-generation antihistamines. J Asthma Allergy 2009;31:73-92
   Google Scholar
• Gillard M, Christophe B, Wels B, et al. H1 antagonists: receptor affinity versus selectivity. Inflamm Res 2003;52(Suppl 1):S49-50
   PubMed Web of Science ®Google Scholar
• Danjou P, Molinier P, Berlin I, et al. Assessment of the anticholinergic effect of the new antihistamine mizolastine in healthy subjects. Br J Clin Pharmacol 1992;34:328-31
   PubMed Web of Science ®Google Scholar
• Radulovic S, Calderon MA, Wilson D, et al. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev 2010;12:CD002893
   PubMed Web of Science ®Google Scholar
• Passalacqua G, Durham SR; Global Allergy and Asthma European Network. Allergic rhinitis and its impact on asthma update: allergen immunotherapy. J Allergy Clin Immunol 2007;119:881-91
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Epstein T. Systemic reactions to subcutaneous allergen immunotherapy. Immunol Allergy Clin North Am 2011;31:241-49
   PubMed Web of Science ®Google Scholar
• Tankersley MS. How should allergists deal with local reactions to allergen immunotherapy? Curr Allergy Asthma Rep 2011;11:115-21
   PubMed Web of Science ®Google Scholar
• Incorvaia C, Masieri S, Scurati S, et al. The current role of sublingual immunotherapy in the treatment of allergic rhinitis in adults and children. J Asthma Allergy 2011;4:13-17
   Google Scholar
• Undesirable effects according to the SPC of Grazax® oral lyophilisate. Available at: http://www.medicines.org.uk/EMC/medicine/19565/SPC/GRAZAX+75%2c000+SQ-T+oral+lyophilisate/#UNDESIRABLE_EFFECTS (accessed January 9th, 2012)
   Google Scholar
• Jáuregui I, Mullol J, Bartra J, et al. H1 antihistamines: psychomotor performance and driving. J Investig Allergol Clin Immunol 2006;16(Suppl 1):37-44
   PubMedGoogle Scholar
• Hansen GR. Loratadine in the high performance aerospace environment. Aviat Space Environ Med 1999;70:919-24
   PubMed Web of Science ®Google Scholar
• Vuurman EF, Rikken GH, Muntjewerff ND, et al. Effects of desloratadine, diphenhydramine, and placebo on driving performance and psychomotor performance measurements. Eur J Clin Pharmacol 2004;60:307-13
   PubMed Web of Science ®Google Scholar
• Brookhuis KA, De Vries G, De Waard D. Acute and subchronic effects of the H1-histamine receptor antagonist ebastine in 10, 20 and 30 mg dose, and triprolidine 10 mg on car driving performance. Br J Clin Pharmacol 1993;36:67-70
   PubMed Web of Science ®Google Scholar
• Verster JC, de Weert AM, Bijtjes SI, et al. Driving ability after acute and sub-chronic administration of levocetirizine and diphenhydramine: a randomized, double-blind, placebo-controlled trial. Psychopharmacology (Berl) 2003;169:84-90
   PubMed Web of Science ®Google Scholar
• Vuurman E, Theunissen E, van Oers A, et al. Lack of effects between rupatadine 10 mg and placebo on actual driving performance of healthy volunteers. Hum Psychopharmacol 2007;22:289-97
   PubMed Web of Science ®Google Scholar
• Ramaekers JG, Uiterwijk MM, O’Hanlon JF. Effects of loratadine and cetirizine on actual driving and psychometric test performance, and EEG during driving. Eur J Clin Pharmacol 1992;42:363-69
   PubMed Web of Science ®Google Scholar
• Ridout F, Shamsi Z, Meadows R, et al. A single-center, randomized, double-blind, placebo-controlled, crossover investigation of the effects of fexofenadine hydrochloride 180 mg alone and with alcohol, with hydroxyzine hydrochloride 50 mg as a positive internal control, on aspects of cognitive and psychomotor function related to driving a car. Clin Ther 2003;25:1518-38
   PubMed Web of Science ®Google Scholar
• Vermeeren A, Ramaekers JG, O'Hanlon JF. Effects of emedastine and cetirizine, alone and with alcohol, on actual driving of males and females. J Psychopharmacol 2002;16:57-64
   PubMed Web of Science ®Google Scholar
• Verster JC, Volkerts ER. Antihistamines and driving ability: evidence from on-the-road driving studies during normal traffic. Ann Allergy Asthma Immunol 2004;92:294-304
   PubMed Web of Science ®Google Scholar
• Verster JC, Mets MAJ. Psychoactive Medication and Traffic Safety. Int J Environ Res Public Health 2009;6:1041-54
   PubMed Web of Science ®Google Scholar
• Sen A, Akin A, Craft KJ, et al. First-generation H1 antihistamines found in pilot fatalities of civil aviation accidents, 1990–2005. Aviat Space Environ Med 2007;78:514-22
   PubMed Web of Science ®Google Scholar
• Bower EA, Moore JL, Moss M, et al. The effects of single-dose fexofenadine, diphenhydramine, and placebo on cognitive performance in flight personnel. Aviat Space Environ Med 2003;74:145-52
   PubMed Web of Science ®Google Scholar
• Product related information for commonly used corticosteroid nasal preparations in the UK. Available at: http://www.medicines.org.uk/EMC/searchresults.aspx?term=nasal&searchtype=QuickSearch (accessed January 9th, 2012)
   Google Scholar
• Product related information for commonly used corticosteroid nasal preparations in the USA. Available at: http://google2.fda.gov/search?q=side+effects+corticosteroid+nasal&client=FDAgov&site=FDAgov&lr=&proxystylesheet=FDAgov&output=xml_no_dtd&getfields=* (accessed January 9th, 2012)
   Google Scholar
• Lombardi C, Gargioni S, Melchiorre A, et al. Safety of sublingual immunotherapy with monomeric allergoid in adults: multicenter post-marketing surveillance study. Allergy 2001;56:989-92
   PubMed Web of Science ®Google Scholar
• Dahl R, Kapp A, Colombo G, et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;118:434-40
   PubMed Web of Science ®Google Scholar
• Scadding G. Optimal management of nasal congestion caused by allergic rhinitis in children: safety and efficacy of medical treatments. Paediatr Drugs 2008;10:151-62
   PubMedGoogle Scholar
• Del Cuvillo A, Sastre J, Montoro J, et al. Use of antihistamines in pediatrics. J Investig Allergol Clin Immunol 2007;17(Suppl 2):28-40
   PubMed Web of Science ®Google Scholar
• Isbister GK, Prior F, Kilham HA. Restricting cough and cold medicines in children. J Paediatr Child Health 2012;48:91-98
   PubMed Web of Science ®Google Scholar
• Merenstein D, Diener-West M, Halbower AC, et al. The trial of infant response to diphenhydramine: the TIRED study - a randomized, controlled, patient-oriented trial. Arch Pediatr Adolesc Med 2006;160:707-12
   PubMed Web of Science ®Google Scholar
• Simons FE. Prospective, long-term safety evaluation of the H1-receptor antagonist cetirizine in very young children with atopic dermatitis. ETAC Study Group. Early Treatment of the Atopic Child. J Allergy Clin Immunol 1999;104(2 Pt 1):433-40
   PubMed Web of Science ®Google Scholar
• Stevenson J, Cornah D, Evrard P, et al. Long-term evaluation of the impact of the h1-receptor antagonist cetirizine on the behavioral, cognitive, and psychomotor development of very young children with atopic dermatitis. Pediatr Res 2002;52:251-57
   PubMedGoogle Scholar
• Simons FE; Early Prevention of Asthma in Atopic Children (EPAAC) Study Group. Safety of levocetirizine treatment in young atopic children: an 18-month study. Pediatr Allergy Immunol 2007;18:535-42
   PubMed Web of Science ®Google Scholar
• Grimfeld A, Holgate ST, Canonica GW, et al. Prophylactic management of children at risk for recurrent upper respiratory infections: the Preventia I Study. Clin Exp Allergy 2004;34:1665-72
   PubMed Web of Science ®Google Scholar
• Bloom M, Staudinger H, Herron J. Safety of desloratadine syrup in children. Curr Med Res Opin 2004;20:1959-65
   PubMed Web of Science ®Google Scholar
• Boner AL, Miglioranzi P, Richelli C, et al. Efficacy and safety of loratadine suspension in the treatment of children with allergic rhinitis. Allergy 1989;44:437-41
   PubMed Web of Science ®Google Scholar
• Milgrom H, Kittner B, Lanier R, et al. Safety and tolerability of fexofenadine for the treatment of allergic rhinitis in children 2 to 5 years old. Ann Allergy Asthma Immunol 2007;99:358-63
   PubMed Web of Science ®Google Scholar
• Lichtenstein SJ, Pasquine TA, Edwards MR, et al. Safety and tolerability of olopatadine 0.2% in children and adolescents. J Ocul Pharmacol Ther 2007;23:366-71
   PubMed Web of Science ®Google Scholar
• Ratner PH, Meltzer EO, Teper A. Mometasone furoate nasal spray is safe and effective for 1-year treatment of children with perennial allergic rhinitis. Int J Pediatr Otorhinolaryngol 2009;73:651-57
   PubMed Web of Science ®Google Scholar
• Máspero JF, Rosenblut A, Finn A Jr, et al. Safety and efficacy of fluticasone furoate in pediatric patients with perennial allergic rhinitis. Otolaryngol Head Neck Surg 2008;138:30-37
   PubMed Web of Science ®Google Scholar
• Schenkel EJ, Skoner DP, Bronsky EA, et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics 2000;105:E22
   PubMed Web of Science ®Google Scholar
• Welch MJ, Bronsky EA, Grossman J, et al. Clinical evaluation of triamcinolone acetonide nasal aerosol in children with perennial allergic rhinitis. Ann Allergy 1991;67:493-98
   PubMedGoogle Scholar
• Knorr B, Franchi LM, Bisgaard H, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics 2001;108:E48
   PubMed Web of Science ®Google Scholar
• Sienra-Monge JJ, Gazca-Aguilar A, Del Rio-Navarro B. Double-blind comparison of cetirizine and loratadine in children ages 2 to 6 years with perennial allergic rhinitis. Am J Ther 1999;6:149-55
   PubMedGoogle Scholar
• Saint-Martin F, Dumur JP, Pérez I, et al. A randomized, double-blind, parallel-group study, comparing the efficacy and safety of rupatadine (20 and 10 mg), a new PAF and H1 receptor-specific histamine antagonist, to loratadine 10 mg in the treatment of seasonal allergic rhinitis. J Investig Allergol Clin Immunol 2004;14:34-40
   PubMed Web of Science ®Google Scholar
• Staevska M, Popov TA, Kralimarkova T, et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy Clin Immunol 2010;125:676-82
   PubMed Web of Science ®Google Scholar
• Pires A, Fortuna A, Alves G, et al. Intranasal drug delivery: how, why and what for? J Pharm Pharm Sci 2009;12:288-311
   PubMed Web of Science ®Google Scholar
• Garlapati RR, Lee HP, Chong FH, et al. Indicators for the correct usage of intranasal medications: a computational fluid dynamics study. Laryngoscope 2009;119:1975-82
   PubMed Web of Science ®Google Scholar
• Garlapati RR, Lee HP, Chong FH, et al. Indicators for the correct usage of intranasal medications: a computational fluid dynamics study. Laryngoscope 2009;119:1975-82
   PubMed Web of Science ®Google Scholar
• Bachert C, El-Akkad T. Patient preferences and sensory comparisons of three intranasal corticosteroids for the treatment of allergic rhinitis. Ann Allergy Asthma Immunol 2002;89:292-97
   PubMed Web of Science ®Google Scholar
• Benninger MS, Hadley JA, Osguthorpe JD, et al. Techniques of intranasal steroid use. Otolaryngol Head Neck Surg 2004;130:5-24
   PubMed Web of Science ®Google Scholar
• Shaikh WA, Shaikh SW. Allergies in India: a study on medication compliance. J Indian Med Assoc 2009;107:462-63
   PubMedGoogle Scholar
• Senna G, Ridolo E, Calderon M, et al. Evidence of adherence to allergen-specific immunotherapy. Curr Opin Allergy Clin Immunol 2009;9:544-48
   PubMed Web of Science ®Google Scholar
• Scurati S, Frati F, Passalacqua G, et al. Adherence issues related to sublingual immunotherapy as perceived by allergists. Patient Prefer Adherence 2010;4:141-45
   PubMed Web of Science ®Google Scholar
• Spangler DL, Brunton S. Efficacy and central nervous system impairment of newer-generation prescription antihistamines in seasonal allergic rhinitis. South Med J 2006;99:593-99
   PubMed Web of Science ®Google Scholar
• Kraft W, Blum RA, Frick GS, et al. Pharmacokinetics (PK) of multiple oral doses of desloratadine (DCL) and fexofenadine (FEX) in a population of healthy adults identified phenotypically as desloratadine slow metabolizers (DSMS). Clin Pharmacol Ther 2005;77:P45
   Web of Science ®Google Scholar
• Weber-Schoendorfer C, Schaefer C. The safety of cetirizine during pregnancy. A prospective observational cohort study. Reprod Toxicol 2008;26:19-23
   PubMed Web of Science ®Google Scholar
• Källén B. Use of antihistamine drugs in early pregnancy and delivery outcome. J Matern Fetal Neonatal Med 2002;11:146-52
   PubMedGoogle Scholar
• Boothby LA, Doering PL. FDA labelling system for drugs in pregnancy. Ann Pharmacother 2001;35:1485-89
   PubMed Web of Science ®Google Scholar
• So M, Bozzo P, Inoue M, et al. Safety of antihistamines during pregnancy and lactation. Can Fam Physician 2010;56:427-29
   PubMed Web of Science ®Google Scholar
• Mann RD, Pearce GL, Dunn N, et al. Sedation with “non-sedating” antihistamines: four prescription-event monitoring studies in general practice. BMJ 2000;320:1184-86
   PubMed Web of Science ®Google Scholar
• Layton D, Wilton L, Boshier A, et al. Comparison of the risk of drowsiness and sedation between levocetirizine and desloratadine: a prescription-event monitoring study in England. Drug Saf 2006;29:897-909
   PubMed Web of Science ®Google Scholar
• Layton D, Wilton L, Shakir SA. Examining the tolerability of the non-sedating antihistamine desloratadine: a prescription-event monitoring study in England. Drug Saf 2009;32:169-79
   PubMed Web of Science ®Google Scholar